GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensorion SA (XPAR:ALSEN) » Definitions » Earnings Yield (Joel Greenblatt) %

Sensorion (XPAR:ALSEN) Earnings Yield (Joel Greenblatt) % : 0.00% (As of Jun. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Sensorion Earnings Yield (Joel Greenblatt) %?

Sensorion's Enterprise Value for the quarter that ended in Jun. 2024 was €129.37 Mil. Sensorion's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was €-23.31 Mil. Sensorion's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2024 was 0.00%.

The historical rank and industry rank for Sensorion's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

XPAR:ALSEN' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -685744.05   Med: -57.9   Max: 30128.01
Current: -20.08

During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Sensorion was 30128.01%. The lowest was -685744.05%. And the median was -57.90%.

XPAR:ALSEN's Earnings Yield (Joel Greenblatt) % is ranked worse than
57.97% of 1361 companies
in the Biotechnology industry
Industry Median: -13.81 vs XPAR:ALSEN: -20.08

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Sensorion's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Sensorion Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Sensorion's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sensorion Earnings Yield (Joel Greenblatt) % Chart

Sensorion Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -60.24 -14.45 -13.87 -322.58 -46.73

Sensorion Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -322.58 - -46.73 -

Competitive Comparison of Sensorion's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Sensorion's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sensorion's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sensorion's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Sensorion's Earnings Yield (Joel Greenblatt) % falls into.



Sensorion Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Sensorions Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-21.593/46.27301
=-46.66 %

For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.



Sensorion  (XPAR:ALSEN) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Sensorion Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Sensorion's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sensorion Business Description

Industry
Traded in Other Exchanges
N/A
Address
375, rue du Professeur Joseph Blayac, Montpellier, FRA, 34080
Sensorion SA is a France-based clinical-stage biotech company dedicated to the development of therapies to restore, treat, and prevent hearing loss. The company's product is in phase 2a clinical development, SENS-401 (Arazasetron) in Sudden Sensorineural Hearing Loss (SSNHL). SENS-401 is being developed to treat cochlear pathologies. The Company does business in a single operating segment: conducting research and development to discover drugs to treat inner ear disorders with a view to their future marketing. The company's pipeline programs are SENS-401 SSNHL, SENS-401 CIO, GJB2-GT, GJB2-GT, SENS-401 Cochlear, and others.

Sensorion Headlines

No Headlines